Lytgobi (Futibatinib) Patent Expiration, LOE Window & CMS Spending

Lytgobi (Futibatinib) by Taiho Oncology: FDA Orange Book core substance LOE 2036-03-31 (last listed 2039-11-05), 0 AB generics, $25.3M 2024 CMS Part D & Medicaid spend, and $5,835 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTaiho Oncology
FDA Application & PathwayN214801 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-03-31
Last Listed Patent or Exclusivity Date2039-11-05
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$25.3M
2024 Medicare Part D Spend$21.8M
2024 Medicaid Spend$3.5M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($5,835 intro WAC)